Number Needed to Treat in Multiple Sclerosis Clinical Trials

Clinicians are expected to select a therapy based on their appraisal of evidence on benefit-to-risk profiles of therapies. In the management of relapsing-remitting multiple sclerosis (RRMS), evidence is typically expressed in terms of risk (proportion) of event, risk reduction, relative and hazard r...

Descripción completa

Detalles Bibliográficos
Autores principales: Okwuokenye, Macaulay, Zhang, Annie, Pace, Amy, Peace, Karl E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447556/
https://www.ncbi.nlm.nih.gov/pubmed/28176189
http://dx.doi.org/10.1007/s40120-017-0063-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447556/
https://www.ncbi.nlm.nih.gov/pubmed/28176189
http://dx.doi.org/10.1007/s40120-017-0063-y

Ejemplares similares